Brief: UCB Presents Dapirolizumab Pegol Phase 3 Data

UCB SA

19/11/2024 06:05

Nov 19 (Reuters) - Ucb SA  UCB.BR :
    * DAPIROLIZUMAB PEGOL PHASE 3 DATA SHOWS SIGNIFICANT
REDUCTION IN
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY
    * DAPIROLIZUMAB PEGOL (DZP) MET ITS PRIMARY ENDPOINT

Source text:  ID:nGNX9FDwjP 
Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))